• Gilead NASH drug fails late stage trial pharmaphorum
    February 13, 2019
    Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.
  • Phase 3 STELLAR-4 Study of Selonsertib Did Not Meet Primary Endpoint americanpharmaceuticalreview
    February 13, 2019
PharmaSources Customer Service